Association Profile

Who We Are

We are a non-profit association based in Sabadell, Spain, made up of a group of volunteers brought together by the common interest in battling leukemia with open-source technologies and open information.

We bring together individuals, companies and organizations to create innovative technologies that can be used in the fight against leukemia and other cancers, and to help bring down the cost of treatment for patients. We are building a network of innovation and collaboration to provide a better future for people and society.

What We Do

  • We create open-source technologies related to the research and detection of Leukemia and other cancers, identifying potential candidates for drugs that can help in the fight against cancer, and to improve efficiency of health and medical organizations, with the goals of reducing the costs of the services they provide to patients.
  • We create open-source technologies for medical use cases including networks, devices and applications.
  • We provide custom development services to businesses and organizations in the health and medical industries.
  • We provide a free student program, Peter Moss Leukemia AI Research Student Program, providing students with an opportunity to learn about Artificial Intelligence and other technologies and their use in medical applications for diagnosis and drug discovery.
  • We provide open information for families, carers, researchers, programmers, students.

Our Mission

Our mission, since 2018, is to advance Leukemia medical research using the latest technologies such as Artificial Intelligence, Internet of Things, Robotics, Virtual/Augmented/Mixed Reality, 3D Design & Printing and Blockchain. We aim to ensure our research, findings, and technologies remain free to anyone that can benefit from their use, whether personal, educational or commercial.

We are creating an "open source" movement for leukemia research and medical technologies. No patents, no proprietary data, no proprietary code. We want to give our tech and our research, to the people!

How We Began

In 2018 the grandfather of Association President, Adam Milton-Barker, was diagnosed terminally ill with Acute Myeloid Leukemia. One month before he was diagnosed he had an all clear blood test, with no signs of Acute Myeloid Leukemia, Adam was convinced that there must have been signs in that blood test that could have given a clue to what was coming the following month.

Adam had previous experience with using Artificial Intelligence for breast cancer detection through the Breast Cancer AI project, and wanted to see this experience could be used to help with Acute Myeloid Leukemia.

Adam created the Peter Moss Acute Myeloid & Lymphoblastic Leukemia AI Research Project, and set out to build a team that would work on open-source classifiers for Leukemia.

11

Team

3

Organizations

20+

Projects

1

Awards

Our Journey Find out about our how our we started and our journey to becoming a non-profit.

2018: How Our Journey Began

The Peter Moss Acute Myeloid & Lymphoblastic Leukemia AI Research Project, was created in 2018 by Adam Milton-Barker after his grandfather was diagnosed with Acute Myeloid Leukemia (AML).

The immediate challenge for Peter's family was finding information and advice that could help them understand how to live with the disease. With AML, there are no known warning signs, so early detection is very hard, if not impossible. In Peter's case, the disease was completely missed in a standard blood test 1 month before.

Adam has a number of years experience developing computer vision and natural language understanding applications, and had previously created a Computer Vision (Artificial Intelligence) project to detect a form of breast cancer known as Invasive Ductal Carcinoma.

A post made in Artificial Intelligence & Deep Learning (AIDL) group on Facebook directed the team to the Acute Lymphoblastic Leukemia Image Database for Image Processing dataset by Fabio Scotti - Associate Professor Dipartimento di Informatica @ Università degli Studi di Milano. This dataset was the foundation of our research for a couple of years.

2019: Our Mission Took Shape

During 2019, the Peter Moss Acute Myeloid & Lymphoblastic Leukemia AI Research Project attracted researchers and developers from throughout the globe and the team was working on open-source classifiers for Acute Lymphoblastic Leukemia which we released through the project Github organization.

Our main project for 2019 was the Peter Moss Acute Lymphoblastic Leukemia Detection System 2019 which we demonstrated and talked about at a number events over the following years.

An important part of the research project was to share information that could help families, carers and programmers. We created an information repository to share open information related to the diseases. This repository grew, and is now the Peter Moss Open Information Database.

Student Program

In 2019 we started a free student program, the Peter Moss Leukemia AI Research Student Program. The aim was to give students a way to work with developers and medical experts to gain real world experience of developing applications for medical use cases.

Estela Cabezas joined the program in 2019 and went on to present our project at Embedded World 2019, Intel Dev Affinity Day 2019 and Codemotion 2019, and used our project as case study in her thesis: Applied Analytics for clinical decision support.

Embedded World

In 2019 we got the opportunity to present the Peter Moss Acute Lymphoblastic Leukemia Detection System 2019 at the Intel booth at Embedded World 2019, Nuremberg, Germany.

Adam and Estela Cabezas visited Germany to join Intel at their booth to present the project, demonstrating the use of Intel technologies for detection of Acute Lymphoblastic Leukemia.

Intel Dev Affinity Day

The team was invited to attend the invite only event Intel Developer Affinity Day at the Intel IoT Lab in Munich in May 2019.

The event was for Intel Software Innovators and Student Ambassadors to meet with Intel staff and executives.

Estela Cabezas represented our team at the event and presented a talk about the Peter Moss Acute Myeloid & Lymphoblastic .

CodeMotion in Madrid

The team was invited to give a speakership @ CodeMotion in Madrid in the Code Motion Diversity In Tech Topic. Estela Cabezas represented our team, giving a talk on the structure and recent developments of the project. This was Estela's second event as an official Intel Software Innovator representing the Peter Moss Acute Myeloid & Lymphoblastic Leukemia AI Research Project.

Intel AI Devmesh Award

The Peter Moss Acute Lymphoblastic Leukemia Detection System 2019 project was based on one of my open-source projects, GeniSysAI and is a featured project on Intel Devmesh.

At the end of 2019 the project was voted 1st in Europe out of 4 projects, and awarded the Intel® DevMesh AI Spotlight Award which was a new designation granted by Intel recognizing inspiring and breakthrough Artificial Intelligence projects in development from the Intel software community.

Peter Passed Away

In August 2019, after battling Acute Myeloid Leukemia for one day short of a year since being terminally diagnosed, Peter sadly passed away.

This was a devastating blow to the family, and made Adam determined to continue the research projects, so that one day our technology and information could play a direct role in the lives of people going through Acute Myeloid Leukemia and other types of leukemia, and their families.

In Peter's memory the team committed to the fight against leukemia.

Peter Moss Leukemia AI Research

In January 2020, Peter Moss Leukemia AI Research was created in the anticipation of forming a non-profit: Asociación de Investigacion en Inteligencia Artificial Para la Leucemia Peter Moss.

For just over a year the team had volunteered their free time to the Peter Moss Acute Myeloid & Lymphoblastic Leukemia AI Research Project, the next natural step was becoming a non-profit.

COVID-19 AI Research Project

In March 2020 the world was plunged into lockdown due to the COVID-19 (SARS-COV-2) pandemic. Our team quickly began to focus our time on COVID-19, our second research project was born: Peter Moss COVID-19 AI Research Project.

On March 18th, Dr Amita Kapoor published COVID 2020 — A data scientist perspective. Soon after her work was referenced in the peer reviewed paper: Covid-19 spread: Reproduction of data and prediction using a SIR model on Euclidean network.

On March 28th, President, Adam Milton-Barker was admitted to Parc Tauli Hospital, Sabadell as a potential COVID-19 patient. During his stay in the hospital Adam was confined in the ICU reception with COVID-19 and potential COVID-19 patients due to the lack of beds available.

Adam was concerned with the amount of time that hospital staff were being exposed to the virus, and an idea began to form for using robots to reduce the risk for medical staff in hospitals that were dealing with the pandemic. From this idea, HIAS - Hospital Intelligent Automation System, EMAR - Emergency Assistance Robot & EMAR Mini were born.

Partnership With PlamenLancaster

Through the Peter Moss COVID-19 AI Research Project we made a very important partnership. In May we teamed up with Plamenlancaster: Professor Plamen Angelov from Lancaster University/ Centre Director @ Lira, & his researcher, Eduardo Soares PhD.

PlamenLancaster pioneered eXplainable Deep Learning and created the SARS-COV-2 Ct-Scan Dataset, a large dataset of CT scans for SARS-CoV-2 (COVID-19) identification.

Asociación de Investigacion en Inteligencia Artificial Para la Leucemia Peter Moss

In June 2020, we finally achieved our goal of becoming a non-profit association, dedicated to fighting Leukema with open-source information and technology. Asociación de Investigacion en Inteligencia Artificial Para la Leucemia Peter Moss emerged from the flames of the COVID-19 pandemic. It was an exciting time for our team, taking us one step closer to to opening a Leukemia Research Hospital.

Melansocan HIAS Pilot Project

In October 2020, we were excited to start a new collaboration with Melanoscan, a biotechnology company in the United States working on Skin Cancer.

With Melanoscan we had the opportunity to take HIAS through it's first pilot project giving our team the first step into the medical industry. The partnership is going very well and we have a lot of projects in the pipeline with Melanoscan.